NOVAVAX INC (NVAX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 330.57M USD | Liabilities, Current |
| Cash and equivalents | 191.46M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 527.88M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 10.01M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $330.57M | $191.46M | $527.88M | (m) | $10.01M | (m) |
| 2026-03-31 | (m) | $342.46M | $228.36M | $561.97M | (m) | $11.46M | (m) |
| 2025-12-31 | (m) | $459.95M | $240.63M | $494.45M | (m) | $11.54M | (m) |
| 2025-09-30 | (m) | $429.87M | $268.02M | $494.87M | (m) | $13.51M | (m) |
| 2025-06-30 | (m) | $389.14M | $253.74M | $358.56M | (m) | $10.24M | (m) |
| 2025-03-31 | (m) | $422.17M | $263.34M | $468.14M | (m) | $10.26M | (m) |
| 2024-12-31 | (m) | $1.15B | $530.23M | $392.89M | (m) | $8.75M | (m) |
| 2024-09-30 | (m) | $1.18B | $573.63M | $335.90M | (m) | $8.64M | (m) |
| 2024-06-30 | (m) | $1.16B | $680.16M | $369.43M | (m) | $9.17M | (m) |
| 2024-03-31 | (m) | $804.38M | $480.59M | (m) | (m) | $15.78M | (m) |
| 2023-12-31 | (m) | $1.64B | $568.50M | (m) | (m) | $41.70M | (m) |
| 2023-09-30 | (m) | $1.47B | $651.10M | (m) | (m) | $69.59M | (m) |
| 2023-06-30 | (m) | $1.60B | $505.91M | (m) | (m) | $23.49M | (m) |
| 2023-03-31 | (m) | $1.92B | $624.95M | (m) | (m) | $34.19M | (m) |
| 2022-12-31 | (m) | $2.46B | $1.34B | (m) | (m) | $36.68M | (m) |
| 2022-09-30 | (m) | $1.67B | $1.28B | (m) | (m) | $82.43M | (m) |
| 2022-06-30 | (m) | $2.16B | $1.38B | (m) | (m) | $256.30M | (m) |
| 2022-03-31 | (m) | $2.26B | $1.57B | (m) | (m) | $106.65M | (m) |
| 2021-12-31 | (m) | $2.39B | $1.52B | $0.00 | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.75B | $1.94B | $0.00 | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.65B | $2.07B | $0.00 | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.21B | $2.00B | $2.25M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $579.67M | $553.40M | $157.65M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $239.22M | $334.17M | $169.86M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $213.33M | $424.39M | $77.90M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $18.98M | $179.88M | $57.47M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $25.80M | $78.82M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $21.57M | $71.17M | $0.00 | (m) | (m) | (m) |
| 2019-06-30 | (m) | $41.49M | $72.00M | $0.00 | (m) | (m) | (m) |
| 2019-03-31 | (m) | $31.50M | $97.71M | $2.48M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $45.54M | $70.15M | $21.98M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $46.72M | $56.50M | $70.61M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $43.02M | $88.47M | $78.64M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $44.90M | $113.40M | $30.36M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $73.67M | $106.31M | $51.00M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $68.28M | $104.25M | $68.32M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $66.79M | $75.79M | $111.52M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $56.50M | $95.85M | $115.33M | (m) | (m) | (m) |
| 2016-12-31 | $235.71M | $66.41M | $144.35M | $91.13M | $233.00K | (m) | 3.55× |
| 2016-09-30 | $300.87M | $75.68M | $119.95M | $180.34M | $591.00K | (m) | 3.98× |
| 2016-06-30 | $366.73M | $81.88M | $89.39M | $276.97M | $363.00K | (m) | 4.48× |
| 2016-03-31 | $434.27M | $71.05M | $132.22M | $301.64M | $406.00K | (m) | 6.11× |
| 2015-12-31 | $232.10M | $76.49M | $93.11M | $137.55M | $1.45M | (m) | 3.03× |
| 2015-09-30 | $292.38M | $24.87M | $138.14M | $152.04M | $2.20M | (m) | 11.76× |
| 2015-06-30 | $317.28M | $27.05M | $167.38M | $147.55M | $2.34M | (m) | 11.73× |
| 2015-03-31 | $334.41M | $28.78M | $215.05M | $112.69M | $6.67M | (m) | 11.62× |
| 2014-12-31 | $175.57M | $34.12M | $32.34M | $135.72M | $7.51M | (m) | 5.15× |
| 2014-09-30 | $180.95M | $18.64M | $34.47M | $143.62M | $2.86M | (m) | 9.71× |
| 2014-06-30 | $156.18M | $17.48M | $103.86M | $48.60M | $3.72M | (m) | 8.94× |
| 2014-03-31 | $117.29M | $13.71M | $109.92M | $2.91M | $4.47M | (m) | 8.55× |
| 2013-12-31 | $134.98M | $18.93M | $119.47M | $13.60M | $1.91M | (m) | 7.13× |
| 2013-09-30 | $148.32M | $14.26M | $122.49M | $23.92M | $1.91M | (m) | 10.40× |
| 2013-06-30 | $41.51M | $11.26M | $2.57M | $38.02M | $907.00K | (m) | 3.69× |
| 2013-03-31 | $46.88M | $9.25M | $9.02M | $35.26M | $2.60M | (m) | 5.07× |
| 2012-12-31 | $45.12M | $11.68M | $17.40M | $26.71M | $1.01M | (m) | 3.86× |
| 2012-09-30 | $30.88M | $10.44M | $10.74M | $17.67M | $2.47M | (m) | 2.96× |
| 2012-06-30 | $28.03M | $9.42M | $15.33M | $11.20M | $1.50M | (m) | 2.98× |
| 2012-03-31 | $22.45M | $7.84M | $13.87M | $6.85M | $1.73M | (m) | 2.86× |
| 2011-12-31 | $20.27M | $7.58M | $14.10M | $4.21M | $1.97M | (m) | 2.68× |
| 2011-09-30 | $19.62M | $6.74M | $14.32M | $5.29M | $17.00K | (m) | 2.91× |
| 2011-06-30 | $24.15M | $8.99M | $13.09M | $9.23M | $1.83M | (m) | 2.69× |
| 2011-03-31 | (m) | (m) | $8.36M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $31.73M | $10.27M | $8.06M | $23.61M | $54.00K | (m) | 3.09× |
| 2010-09-30 | (m) | (m) | $16.21M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $9.45M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $38.76M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $26.94M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |